Groupe Athena in Final Discussions for Manufacture of Atorvastatin

Life Science Investing News

Groupe Athena, Inc. (OTCPINK:GATA) reported that they are in the final stages of negotiations with 2 Indian pharmaceutical companies for the manufacture of Atorvastatin, the generic form of Lipitor.

Groupe Athena, Inc. (OTCMKTS:GATA) reported that they are in the final stages of negotiations with 2 Indian pharmaceutical companies for the manufacture of Atorvastatin, the generic form of Lipitor.

As quoted in the press release:

The company expects to finalize terms by the end of April with formal license application to the UK MHRA expected to follow by mid year.
As was previously announced, the initial license application will be for the manufacture and sale of 25 and 50 mg Atorvastatin. The UK National Health Service states that it is saving approximately $1 million GBP per day on Atorvastatin since the Lipitor patent expiration.

Click here to read the Groupe Athena (OTCPINK:GATA) press release